분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2011-12-13 11:49:04 , Hit : 2671
 Vertex begins joint studies on hepatitis C compounds

Friday, December 9, 2011

By Michelle Lang
Vertex Pharmaceuticals Inc. has launched two clinical studies with California biotech Alios BioPharma Inc. to test treatments for hepatitis C virus.

The Cambridge biotech holds global development and commercialization rights to Alios-discovered compounds, ALS-2200 and ALS-2158, through a licensing deal made in June.  The trials, to be conducted jointly by Vertex and Alios, are designed to measure the safety and tolerability of ascending doses of each of the compounds in healthy patients and in patients with chronic genotype-1 hepatitis C. A secondary evaluation will measure the compounds’ effects on viral kinetics.

Vertex said in a news release that it plans to move ALS-2200 and ALS-2158 into Phase 2 studies in the second half of 2012 that will evaluate the compounds in combinations with Vertex hepatitis C drug, Incivek (teleprevir), approved in the U.S. in May, or with VX-222, a Vertex-developed oral drug that is a non-nucleoside inhibitor of the HCV NS5B polymerase.

The June licensing agreement Vertex formed with Alios calls for the Cambridge company to pay Alios a $60 million up front payment, plus research and development costs of the ALS-2200 and ALS-2158 compounds, in exchange for worldwide rights to the drug candidates. If both drugs are approved, Vertex could ultimately pay up to $715 million in R&D milestone payments, as well as up to $750 million more in both drug candidates meet sales milestones.










827   Vertex study will evaluate 12-week treatment period for some hepatitis C patients  이성욱 2011/10/25 2889
826   MicroRNAs Prevent Cell Reprogramming  이성욱 2011/10/27 3645
825   Going Viral  이성욱 2011/10/28 2663
824   GlaxoSmithKline is first partner for new Alnylam platform  이성욱 2011/11/02 2580
823   Do Bacteria Age? Biologists Discover the Answer Follows Simple Economics  이성욱 2011/11/04 2440
822   Regular Aspirin Intake Halves Cancer Risk, Study Finds  이성욱 2011/11/04 2403
821   Gene Therapy Shows Promise as Hemophilia Treatment in Animal Studies  이성욱 2011/11/10 2487
820   How Blood Cells Thwart Malaria  이성욱 2011/11/13 3419
819   Pox Vaccine Treats Liver Cancer - Smallpox vaccine extends life in cancer trial-  이성욱 2011/11/13 2693
818   AASLD: African-Americans Face Hep C 'Triple Whammy'  이성욱 2011/11/17 2410
817   Uncovering a Key Player in Metastasis  이성욱 2011/11/21 2612
816   Finger (mal)formation reveals surprise function of desert DNA  이성욱 2011/11/28 2768
815   Stem-cell pioneer bows out  이성욱 2011/11/28 2487
814   Genetic variant linked to development of liver cancer in hepatitis C virus carriers  이성욱 2011/12/03 2665
813   Treatment for Blood Disease Is Gene Therapy Landmark  이성욱 2011/12/13 2032
  Vertex begins joint studies on hepatitis C compounds  이성욱 2011/12/13 2671
811   Former Reginans changing the future of HIV  이성욱 2011/12/28 2311
810   The RNA roots of obesity?  이성욱 2012/01/03 2293
809   Alnylam Cuts One-Third of Workforce, To Save Cash for RNAi Clinical Plans  이성욱 2012/01/22 2488
808   Can DNA Self-replicate?  이성욱 2012/01/22 2493

[이전 10개] [1]..[21][22] 23 [24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN